Compare Amgen, Inc. (AMGN) vs Ross Stores, Inc. (ROST) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Ross Stores, Inc. — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Ross Stores, Inc. trades at $222 (market cap $71.50B). The key difference: Amgen, Inc. is far larger — about 2.7× Ross Stores, Inc.'s market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | ROST | |
|---|---|---|
Market Cap | $196.12B | $71.50B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $240.13 |
52-Week Low | $271.18 | $127.59 |
Enterprise Value | $241.41B | $72.09B |
Dividend Yield | 2.77% | 0.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Ross Stores (ROST) trades at $222.88, up 1.02% with strong momentum near recent highs. The stock shows bullish technical signals with consistent earnings beats in recent quarters (Q3 2025-Q1 2026) and robust fundamentals including 38.98% ROE and 9.74% net margin. Revenue growth accelerated to $21.13B in 2025, with analyst consensus strongly favoring Buy ratings (63.83%) and a $259 price target representing 16% upside potential.
Outlook remains positive given strong operational execution and consumer demand, though valuation multiples (P/E 31.13) appear elevated. Key risks include retail sector competition and economic sensitivity. Institutional sentiment supports further gains if earnings momentum continues through Q2 2026 results.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Ross Stores, Inc.
Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach
Read more on ROST →
